Lexicon Pharmaceuticals Inc

NASDAQ: LXRX
$1.71
+$0.06 (+3.6%)
Closing price April 22, 2024
Lexicon Pharmaceuticals Inc is a biopharmaceutical company based in The Woodlands, Texas, dedicated to developing pharmaceutical products. It focuses on creating orally-delivered small molecule drugs for conditions like heart failure, type 1 diabetes, and neuropathic pain. Its leading drug candidates include Sotagliflozin, in advanced clinical trials for heart failure and diabetes, and LX9211 and LX2761, targeting neuropathic pain and gastrointestinal issues, respectively. Lexicon also collaborates with industry giants like Bristol-Myers Squibb and Genentech to enhance its research and development efforts.
Friday's additional top analyst upgrades and downgrades were on Ciena, Lennar, Lexicon Pharmaceuticals, Mister Car Wash, PagerDuty, RealReal, Six Flags and more.
The Friday afternoon analyst calls were focused on Biogen, 3D Systems, Duke Energy, Ford, and more.
Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
24/7 Wall St. has compiled a list of some speculative biotech plays that could see gains of up to 300% in the coming months.
Lexicon Pharmaceuticals shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes.
After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.
Lexicon Pharma shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm.
Lexicon shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on the Marketing Authorization of Zynquista...
Vodafone, Lexicon Pharmaceuticals, Amneal Pharmaceuticals, and Maiden Holding had all posted new 52-week lows by noon Friday.
Immunomedics, Signet Jewelry, Nautilus, and Lexicon Pharmaceuticals had all posted new 52-week lows by noon Friday.
Lexicon shares fell on Friday after the FDA voted to approve the firm’s type 1 diabetes treatment. Although the result from this committee was mixed, it seems to be a case of sell the news.
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
The top analyst upgrades, downgrades and other research calls from Monday include American Electric Power, American Water Works, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald's and...
These top picks from Wedbush offer varying degrees of risk and upside. The fact that they are not crowded momentum plays makes them far more attractive for the rest of 2017 and into next year.